Invention Grant
- Patent Title: Glucose oxidase compositions as a neonate anticonvulsant
-
Application No.: US16957087Application Date: 2019-01-03
-
Publication No.: US11666640B2Publication Date: 2023-06-06
- Inventor: Gong Chen , Zheng Wu
- Applicant: PENN STATE RESEARCH FOUNDATION
- Applicant Address: US PA University Park
- Assignee: PENN STATE RESEARCH FOUNDATION
- Current Assignee: PENN STATE RESEARCH FOUNDATION
- Current Assignee Address: US PA University Park
- Agency: Arnold & Porter Kaye Scholer LLP
- International Application: PCT/US2019/012208 2019.01.03
- International Announcement: WO2019/136168A 2019.07.11
- Date entered country: 2020-06-22
- Main IPC: A61K38/44
- IPC: A61K38/44 ; A61P25/08

Abstract:
Neonatal seizure is different from adult seizure, and many anti epileptic drugs that are effective in adults often fail to treat neonatal seizure. Gluconic acid, a natural organic acid enriched in fruits and honey, and the glucose oxidase enzyme, is shown herein to potently inhibit neonatal epilepsy both in vitro and in vivo. Sodium gluconate is shown to inhibit epileptiform burst activity in cell cultures and protect neurons from kainic acid-induced cell death. Sodium gluconate also inhibited epileptiform burst activity in brain slices in a manner that was much more potent in neonatal animals than in older animals. Consistently, in vivo EEC recordings also revealed that sodium gluconate inhibited the epileptic seizure activity in a manner that was much more potent in neonates than in adult animals. Mechanistically, sodium gluconate inhibits voltage-dependent CLC-3 C1− channels both in neuronal cultures and in hippocampal slices. Together, these data suggest a novel antiepileptic drug gluconate that potently inhibits neonatal seizures through blocking CLC-3 C1− channels.
Public/Granted literature
- US20200345817A1 GLUCOSE OXIDASE COMPOSITIONS AS A NEONATE ANTICONVULSANT Public/Granted day:2020-11-05
Information query
IPC分类: